Results 171 to 180 of about 756,852 (217)
Efgartigimod in Very-Late-Onset Generalized Myasthenia Gravis: A Real-World Study on Effectiveness and Safety. [PDF]
Curr NeuropharmacolMa C, Shen J, Zhu Y, Wang B, Zhu R.
europepmc +1 more source
Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis [PDF]
JAMA Neurology, 2020 Use of biologic agents in generalized myasthenia gravis is generally limited to therapy-refractory cases; benefit in new-onset disease is unknown.To assess rituximab in refractory and new-onset generalized myasthenia gravis and rituximab vs conventional immunotherapy in new-onset disease.A retrospective cohort study with prospectively collected data ...
Fredrik Piehl +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Methotrexate in generalized myasthenia gravis: a systematic review
Acta Neurologica Belgica, 2023Current myasthenia gravis guidelines recommend the use of azathioprine as first-line steroid sparing agent. However, due to its high cost, compliance to azathioprine is low in developing countries. To determine the efficacy and safety of the cheaper methotrexate as an alternative immunosuppressant, Medline/Pubmed, Embase and Cochrane databases and ...
Mario B. Prado, Karen Joy B. Adiao
openaire +2 more sources
Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis
Journal of Neuro-Ophthalmology, 2003Several retrospective studies have suggested that immunotherapy, including prednisolone, azathioprine and thymectomy, reduces progression of ocular myasthenia gravis to generalized myasthenia gravis. This study examines the effect of immunotherapy on generalization rates in ocular myasthenia patients who are acetylcholine receptor (AChR) antibody ...
Jared, Mee +5 more
openaire +2 more sources
Plasmapheresis in Refractory Generalized Myasthenia Gravis
Archives of Neurology, 1981A group of 16 patients with severe generalized myasthenia gravis (MG) (five with thymoma) that was resistant to anticholinesterases, thymectomy, and corticosteroids were treated by plasmapheresis. Twelve patients showed an excellent clinical response.
P, Kornfeld +6 more
openaire +2 more sources
Hypereosinophilic syndrome with generalized myasthenia gravis
The Journal of Pediatrics, 1996A patient with hypereosinophilic syndrome simultaneously had generalized myasthenia gravis. Ultrastructural and functional studies demonstrated an increase of the activated hypodense eosinophils. The eosinophilic cationic protein level in plasma and whole blood paralleled the severity of congestive heart failure.
Y, Ishida +6 more
openaire +2 more sources
Causes of symptom dissatisfaction in patients with generalized myasthenia gravis
Journal of Neurology, 2021Patient-centered assessments have attracted increasing attention in the last decade in clinics and research. The purpose of this study was to examine the association between patients' satisfaction with symptoms and several disease-specific and generic outcome measures in 100 patients with generalized myasthenia gravis (gMG).In this cross-sectional ...
Linda Kahr Andersen +3 more
openaire +3 more sources
Corticotropin in Generalized Myasthenia Gravis
JAMA, 1966The effect of short, intensive courses of corticotropin (100 units intravenously, daily for ten days) was studied in patients with generalized myasthenia gravis. A decrease in strength and response to anticholinesterase medication occurred during 21 of 22 courses in seven of eight patients.
openaire +1 more source